Metastatic renal cell carcinoma treated with sunitinib: Early evaluation of treatment response using dynamic contrast-enhanced ultrasonography

Clinical Cancer Research

Volumn 16, Issue 4, 2010, Pages 1216-1225

  Lassau, Nathalie ^a   Koscielny, Serge ^a   Albiges, Laurence ^a   Chami, Linda ^a   Benatsou, Baya ^a   Chebil, Mohamed ^a   Roche, Alain ^a   Escudier, Bernard J ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

SUNITINIB;

ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DISEASE FREE SURVIVAL; DRUG EFFICACY; ECHOGRAPHY; FEMALE; HUMAN; KIDNEY CARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SOLID TUMOR; TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CONTRAST MEDIA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; NEOPLASM METASTASIS; PROGNOSIS; PYRROLES; ULTRASONOGRAPHY;

EID: 76749170854     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2175     Document Type: Article

References (22)

1. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
2. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib versus interferon-α in first-line treatment of patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:3584-90.
3. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
4. Lassau N, Chami L, Benatsou B, Peronneau P, Roche A. Dynamic contrast-enhanced ultrasonography (DCE-US) with quantification of tumor perfusion: a new diagnostic tool to evaluate the early effects of antiangiogenic treatment. Eur Radiol 2007;17 Suppl 6:F89-98.
5. Cosgrove D. Angiogenesis imaging-ultrasound. Br J Radiol 2003;76: Spec No 1:S43-9.
6. Lassau N, Koscielny S, Opolon P, et al. Evaluation of contrastenhanced color Doppler ultrasound for the quantification of angiogenesis in vivo. Invest Radiol 2001;36:50-5.
7. Lamuraglia M, Escudier B, Chami L, et al. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer 2006;42:2472-9.
8. Escudier B, Lassau N, Angevin E, et al. Phase I trial of sorafenib in combination with IFN-α-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 2007;13:1801-9.
9. Lassau N, Lamuraglia M, Chami L, et al. Gastrointestinal stromal tumours treated with imatinib: monitoring response with contrastenhanced sonography. AJR Am J Roentgenol 2006;187:1267-3.
10. Miles KA. Measurement of tissue perfusion by dynamic computed tomography. Br J Radiol 1991;64:409-12.
11. Mullani NA, Gould KL. First-pass measurements of regional blood flow with external detectors. J Nucl Med 1983;24:577-81.
12. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
13. Chen MY, Bechtold RE, Savage PD. Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate). AJR Am J Roentgenol 2002;79:1059-62.
14. Ray-Coquard I, Le CA, Michallet V, et al. Gastro-intestinal stromal tumors: news and comments. Bull Cancer 2003;90:69-76.
15. Blay JY, Landi B, Bonvalot S, Ray-Coquard I. Recommendations for the management of GIST patients. Bull Cancer 2005;92:907-18.
16. Choi H, Faria S, Benjamin R, et al. Monitoring treatment effects of STI-571 on gastrointestinal stromal tumors (GIST) with CT and PET: a quantitative analysis. RSNA Scientific Program 2002, (abstract 583).
17. Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007;25:1760-4.
18. Stroobants S, Goeminne J, Seegers M, et al. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003;39:12-2020.
19. Young H, Baum R, Cremerius U, et al, European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer 1999;35:1773-82.
20. Gayed I, Vu T, Iyer R, et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 2004;45:17-21.
21. Antoch G, Kanja J, Bauer S, et al. Comparison of PET, CT, and dualmodality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004;45: 357-65.
22. Rouffiac V, Bouquet C, Lassau N, et al. Validation of a new method for quantifying in vivo murine tumor necrosis by sonography. Invest Radiol 2004;39:350-6.